Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine

Journal of Immunology

Volumn 189, Issue 11, 2012, Pages 5367-5381

  Planque, Stephanie A ^a   Mitsuda, Yukie ^a   Nishiyama, Yasuhiro ^a   Karle, Sangeeta ^a   Boivin, Stephane ^a   Salas, Maria ^b   Morris, Mary Kate ^b   Hara, Mariko ^a   Liao, Guangling ^a,d   Massey, Richard J ^c   Hanson, Carl V ^b   Paul, Sudhir ^a,c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

^c Covalent Bioscience ^*  (United States)

^d UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 BINDING DETERMINATE; EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; LYMPHOCYTE ANTIGEN RECEPTOR; NEUTRALIZING ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANTIGEN RECOGNITION; ARTICLE; BINDING SITE; CHROMATOGRAPHY; CONTROLLED STUDY; EXPOSURE; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MOUSE; MUTATION; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; VIRUS NEUTRALIZATION; VIRUS STRAIN;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; SUPERANTIGENS;

EID: 84869790970     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200981     Document Type: Article

References (71)

1. Pantophlet, R., and D. R. Burton. 2006. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24: 739-769.
2. Zhou, T., L. Xu, B. Dey, A. J. Hessell, D. Van Ryk, S. H. Xiang, X. Yang, M. Y. Zhang, M. B. Zwick, J. Arthos, et al. 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445: 732-737. (Pubitemid 46279718)
3. Zhou, T., I. Georgiev, X. Wu, Z. Y. Yang, K. Dai, A. Finzi, Y. D. Kwon, J. F. Scheid, W. Shi, L. Xu, et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329: 811-817.
4. Planque, S., M. Salas, Y. Mitsuda, M. Sienczyk, M. A. Escobar, J. P. Mooney, M. K. Morris, Y. Nishiyama, D. Ghosh, A. Kumar, et al. 2010. Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection. AIDS 24: 875-884.
5. Herrera, C., C. Spenlehauer, M. S. Fung, D. R. Burton, S. Beddows, and J. P. Moore. 2003. Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site. J. Virol. 77: 1084-1091. (Pubitemid 36055530)
6. Spearman, P., M. A. Lally, M. Elizaga, D. Montefiori, G. D. Tomaras, M. J. McElrath, J. Hural, S. C. De Rosa, A. Sato, Y. Huang, et al HIV Vaccine Trials Network of NIAID. 2011. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J. Infect. Dis. 203: 1165-1173.
7. Binley, J. M., T. Wrin, B. Korber, M. B. Zwick, M. Wang, C. Chappey, G. Stiegler, R. Kunert, S. Zolla-Pazner, H. Katinger, et al. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78: 13232-13252. (Pubitemid 39507829)
8. Zwick, M. B., L. L. Bonnycastle, A. Menendez, M. B. Irving, C. F. Barbas, III, P. W. Parren, D. R. Burton, and J. K. Scott. 2001. Identification and characterization of a peptide that specifically binds the human, broadly neutralizing antihuman immunodeficiency virus type 1 antibody b12. J. Virol. 75: 6692-6699. (Pubitemid 32578189)
9. Janeway, C., P. Travers, M. Walport, and M. J. Schlomchik. 2005. The Generation of Lymphocyte Antigen Receptors. In Immunobiology: The Immune System in Health and Disease, 6th Ed. Garland Science Publishing, New York, p. 135-168.
10. Chen, W., E. D. Streaker, D. E. Russ, Y. Feng, P. Prabakaran, and D. S. Dimitrov. 2012. Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: implications for mechanisms of immune evasion and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 417: 1164-1169.
11. Wu, X., T. Zhou, J. Zhu, B. Zhang, I. Georgiev, C. Wang, X. Chen, N. S. Longo, M. Louder, K. McKee, et al NISC Comparative Sequencing Program. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333: 1593-1602.
12. Scheid, J. F., H. Mouquet, B. Ueberheide, R. Diskin, F. Klein, T. Y. Oliveira, J. Pietzsch, D. Fenyo, A. Abadir, K. Velinzon, et al. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333: 1633-1637.
13. Kwong, P. D., R. Wyatt, J. Robinson, R. W. Sweet, J. Sodroski, and W. A. Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659. (Pubitemid 28289647)
14. core. Science 310: 1025-1028.
15. Olshevsky, U., E. Helseth, C. Furman, J. Li, W. Haseltine, and J. Sodroski. 1990. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J. Virol. 64: 5701-5707.
16. Pantophlet, R., E. Ollmann Saphire, P. Poignard, P. W. Parren, I. A. Wilson, and D. R. Burton. 2003. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol. 77: 642-658. (Pubitemid 36005001)
17. Goodglick, L., N. Zevit, M. S. Neshat, and J. Braun. 1995. Mapping the Ig superantigen-binding site of HIV-1 gp120. J. Immunol. 155: 5151-5159.
18. Karray, S., and M. Zouali. 1997. Identification of the B cell superantigen-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. USA 94: 1356-1360.
19. Paul, S., S. Karle, S. Planque, H. Taguchi, M. Salas, Y. Nishiyama, B. Handy, R. Hunter, A. Edmundson, and C. Hanson. 2004. Naturally occurring proteolytic antibodies: selective immunoglobulin M-catalyzed hydrolysis of HIV gp120. J. Biol. Chem. 279: 39611-39619. (Pubitemid 39258228)
20. Planque, S., Y. Mitsuda, H. Taguchi, M. Salas, M. K. Morris, Y. Nishiyama, R. Kyle, P. Okhuysen, M. Escobar, R. Hunter, et al. 2007. Characterization of gp120 hydrolysis by IgA antibodies from humans without HIV infection. AIDS Res. Hum. Retroviruses 23: 1541-1554.
21. Silverman, G. J., and C. S. Goodyear. 2006. Confounding B-cell defences: lessons from a staphylococcal superantigen. Nat. Rev. Immunol. 6: 465-475.
22. Berberian, L., L. Goodglick, T. J. Kipps, and J. Braun. 1993. Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science 261: 1588-1591. (Pubitemid 23319603)
23. Karray, S., L. Juompan, R. C. Maroun, D. Isenberg, G. J. Silverman, and M. Zouali. 1998. Structural basis of the gp120 superantigen-binding site on human immunoglobulins. J. Immunol. 161: 6681-6688. (Pubitemid 28562210)
24. Neshat, M. N., L. Goodglick, K. Lim, and J. Braun. 2000. Mapping the B cell superantigen binding site for HIV-1 gp120 on a V(H)3 Ig. Int. Immunol. 12: 305-312. (Pubitemid 30142702)
25. Sun, N. C., D. D. Ho, C. R. Sun, R. S. Liou, W. Gordon, M. S. Fung, X. L. Li, R. C. Ting, T. H. Lee, N. T. Chang, and T. W. Chang. 1989. Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120. J. Virol. 63: 3579-3585. (Pubitemid 19205426)
26. Kelker, H. C., V. R. Itri, and F. T. Valentine. 2010. A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein. PLoS One 5: e8555.
27. Goodyear, C. S., and G. J. Silverman. 2005. B cell superantigens: a microbe's answer to innate-like B cells and natural antibodies. Springer Semin. Immunopathol. 26: 463-484. (Pubitemid 40468897)
28. Planque, S., Y. Nishiyama, H. Taguchi, M. Salas, C. Hanson, and S. Paul. 2008. Catalytic antibodies to HIV: physiological role and potential clinical utility. Autoimmun. Rev. 7: 473-479.
29. Townsley-Fuchs, J., L. Kam, R. Fairhurst, S. J. Gange, L. Goodglick, J. V. Giorgi, N. Sidell, R. Detels, and J. Braun. 1996. Human immunodeficiency virus-1 (HIV-1) gp120 superantigen-binding serum antibodies: a host factor in homosexual HIV-1 transmission. J. Clin. Invest. 98: 1794-1801. (Pubitemid 26359196)
30. Llorente, M., S. Sánchez-Palomino, S. Mañes, P. Lucas, L. Kremer, I. M. De Alborán, J. L. Torán, J. Alcamí, G. Del Real, and C. Martínez-A. 1999. Natural human antibodies retrieved by phage display libraries from healthy donors: polyreactivity and recognition of human immunodeficiency virus type 1gp120 epitopes. Scand. J. Immunol. 50: 270-279. (Pubitemid 29399900)
31. Planque, S., H. Taguchi, G. Burr, G. Bhatia, S. Karle, Y. X. Zhou, Y. Nishiyama, and S. Paul. 2003. Broadly distributed chemical reactivity of natural antibodies expressed in coordination with specific antigen binding activity. J. Biol. Chem. 278: 20436-20443. (Pubitemid 36799246)
32. Paul, S., S. Planque, Y. X. Zhou, H. Taguchi, G. Bhatia, S. Karle, C. Hanson, and Y. Nishiyama. 2003. Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120. J. Biol. Chem. 278: 20429-20435. (Pubitemid 36799245)
33. Karle, S., Y. Nishiyama, H. Taguchi, Y. X. Zhou, J. Luo, S. Planque, C. Hanson, and S. Paul. 2003. Carrier-dependent specificity of antibodies to a conserved peptide determinant of gp120. Vaccine 21: 1213-1218. (Pubitemid 36139951)
34. Nishiyama, Y., G. Bhatia, Y. Bangale, S. Planque, Y. Mitsuda, H. Taguchi, S. Karle, and S. Paul. 2004. Toward selective covalent inactivation of pathogenic antibodies: a phosphate diester analog of vasoactive intestinal peptide that inactivates catalytic autoantibodies. J. Biol. Chem. 279: 7877-7883. (Pubitemid 38294674)
35. Mitsuda, Y., S. Planque, M. Hara, R. Kyle, H. Taguchi, Y. Nishiyama, and S. Paul. 2007. Naturally occurring catalytic antibodies: evidence for preferred development of the catalytic function in IgA class antibodies. Mol. Biotechnol. 36: 113-122. (Pubitemid 350135917)
36. Karle, S., S. Planque, Y. Nishiyama, H. Taguchi, Y. X. Zhou, M. Salas, D. Lake, P. Thiagarajan, F. Arnett, C. V. Hanson, and S. Paul. 2004. Cross-clade HIV-1 neutralization by an antibody fragment from a lupus phage display library. AIDS 18: 329-331. (Pubitemid 38253459)
37. Taguchi, H., S. Planque, G. Sapparapu, S. Boivin, M. Hara, Y. Nishiyama, and S. Paul. 2008. Exceptional amyloid beta peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds. J. Biol. Chem. 283: 36724-36733.
38. Nishiyama, Y., S. Planque, Y. Mitsuda, G. Nitti, H. Taguchi, L. Jin, J. Symersky, S. Boivin, M. Sienczyk, M. Salas, et al. 2009. Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity. J. Biol. Chem. 284: 30627-30642.
39. McLean, G. R., A. Nakouzi, A. Casadevall, and N. S. Green. 2000. Human and murine immunoglobulin expression vector cassettes. Mol. Immunol. 37: 837-845.
40. Moody, M. A., H. X. Liao, S. M. Alam, R. M. Scearce, M. K. Plonk, D. M. Kozink, M. S. Drinker, R. Zhang, S. M. Xia, L. L. Sutherland, et al. 2010. Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J. Exp. Med. 207: 763-776.
41. Taketa-Graham, M., J. L. Powell Pereira, E. Baylis, C. Cossen, L. Oceguera, P. Patiris, R. Chiles, C. V. Hanson, and B. Forghani. 2010. High throughput quantitative colorimetric microneutralization assay for the confirmation and differentiation of West Nile virus and St. Louis encephalitis virus. Am. J. Trop. Med. Hyg. 82: 501-504.
42. Reed, J., and V. Kinzel. 1991. A conformational switch is associated with receptor affinity in peptides derived from the CD4-binding domain of gp120 from HIV I. Biochemistry 30: 4521-4528.
43. Robey, F. A., T. Harris-Kelson, M. Robert-Guroff, D. Batinić, B. Ivanov, M. S. Lewis, and P. P. Roller. 1996. A synthetic conformational epitope from the C4 domain of HIV Gp120 that binds CD4. J. Biol. Chem. 271: 17990-17995. (Pubitemid 26250784)
44. Gehenn, K., R. Pipkorn, and J. Reed. 2004. Successful design and synthesis of a polarity-triggered beta - >alpha conformational switch using the side chain interaction index (SCII) as a measure of local structural stability. Biochemistry 43: 607-612. (Pubitemid 38114047)
45. Bermas, B. L., M. Petri, J. A. Berzofsky, A. Waisman, G. M. Shearer, and E. Mozes. 1994. Binding of glycoprotein 120 and peptides from the HIV-1 envelope by autoantibodies in mice with experimentally induced systemic lupus erythematosus and in patients with the disease. AIDS Res. Hum. Retroviruses 10: 1071-1077. (Pubitemid 24314302)
46. Daikh, B. E., and M. M. Holyst. 2001. Lupus-specific autoantibodies in concomitant human immunodeficiency virus and systemic lupus erythematosus: case report and literature review. Semin. Arthritis Rheum. 30: 418-425. (Pubitemid 32565328)
47. Lefranc, M. P., and G. Lefranc. 2001. The Immunoglobulin FactsBook. Academic Press, London.
48. Nishiyama, Y., S. Karle, S. Planque, H. Taguchi, and S. Paul. 2007. Antibodies to the superantigenic site of HIV-1 gp120: hydrolytic and binding activities of the light chain subunit. Mol. Immunol. 44: 2707-2718. (Pubitemid 46240317)
49. MacCallum, R. M., A. C. Martin, and J. M. Thornton. 1996. Antibody-antigen interactions: contact analysis and binding site topography. J. Mol. Biol. 262: 732-745. (Pubitemid 26343518)
50. Casali, P., and E. W. Schettino. 1996. Structure and function of natural antibodies. Curr. Top. Microbiol. Immunol. 210: 167-179. (Pubitemid 26024271)
51. Scherl, M., U. Posch, G. Obermoser, C. Ammann, N. Sepp, H. Ulmer, M. P. Dierich, H. Stoiber, and B. Falkensammer. 2006. Targeting human immunodeficiency virus type 1 with antibodies derived from patients with connective tissue disease. Lupus 15: 865-872. (Pubitemid 46049691)
52. Krakauer, T. 2002. Stimulant-dependent modulation of cytokines and chemokines by airway epithelial cells: cross talk between pulmonary epithelial and peripheral blood mononuclear cells. Clin. Diagn. Lab. Immunol. 9: 126-131. (Pubitemid 34084287)
53. Koning, F. A., D. Kwa, B. Boeser-Nunnink, J. Dekker, J. Vingerhoed, H. Hiemstra, and H. Schuitemaker. 2003. Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. J. Infect. Dis. 188: 864-872. (Pubitemid 37176033)
54. Geonnotti, A. R., M. Bilska, X. Yuan, C. Ochsenbauer, T. G. Edmonds, J. C. Kappes, H. X. Liao, B. F. Haynes, and D. C. Montefiori. 2010. Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production. AIDS Res. Hum. Retroviruses 26: 279-291.
55. Annunziato, F., G. Galli, F. Nappi, L. Cosmi, R. Manetti, E. Maggi, B. Ensoli, and S. Romagnani. 2000. Limited expression of R5-tropic HIV-1 in CCR5-positive type 1-polarized T cells explained by their ability to produce RANTES, MIP-1alpha, and MIP-1beta. Blood 95: 1167-1174. (Pubitemid 30099822)
56. Jobe, O., K. K. Peachman, G. R. Matyas, L. V. Asher, C. R. Alving, and M. Rao. 2012. An anti-phosphoinositide-specific monoclonal antibody that neutralizes HIV-1 infection of human monocyte-derived macrophages. Virology 430: 110-119.
57. Goodyear, C. S., F. Sugiyama, and G. J. Silverman. 2006. Temporal and dose-dependent relationships between in vivo B cell receptor-targeted proliferation and deletion-induced by a microbial B cell toxin. J. Immunol. 176: 2262-2271. (Pubitemid 43201673)
58. Mitsuda, Y., S. Planque, D. Ghosh, Y. Nishiyama, C. V. Hanson, and S. Paul. 2010. Correction of deficient class-switched antibody response to the CD4 binding site by covalent immunization. In AIDS 2010: XVIII International AIDS Conference, July 18-23. Vienna, Austria. Abtract #MOPE0045. Poster available at http://pag.aids2010.org/PDF/10575.pdf
59. Wolbank, S., R. Kunert, G. Stiegler, and H. Katinger. 2003. Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) antihuman immunodeficiency virus type 1 antibodies 2F5 and 2G12. J. Virol. 77: 4095-4103. (Pubitemid 36350949)
60. Kunert, R., S. Wolbank, G. Stiegler, R. Weik, and H. Katinger. 2004. Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res. Hum. Retroviruses 20: 755-762. (Pubitemid 39037507)
61. Van Regenmortel, M. H. 2012. Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine. Arch. Virol. 157: 1-20.
62. Neurath, A. R., N. Strick, and E. S. Lee. 1990. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides. J. Gen. Virol. 71: 85-95. (Pubitemid 20046013)
63. Morrow, W. J., W. M. Williams, A. S. Whalley, T. Ryskamp, R. Newman, C. Y. Kang, S. Chamat, H. Köhler, and T. Kieber-Emmons. 1992. Synthetic peptides from a conserved region of gp120 induce broadly reactive anti-HIV responses. Immunology 75: 557-564.
64. Brown, B. K., L. Wieczorek, E. Sanders-Buell, A. Rosa Borges, M. L. Robb, D. L. Birx, N. L. Michael, F. E. McCutchan, and V. R. Polonis. 2008. Crossclade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 375: 529-538.
65. Rusert, P., A. Mann, M. Huber, V. von Wyl, H. F. Gunthard, and A. Trkola. 2009. Divergent effects of cell environment on HIV entry inhibitor activity. AIDS 23: 1319-1327.
66. Mann, A. M., P. Rusert, L. Berlinger, H. Kuster, H. F. Günthard, and A. Trkola. 2009. HIV sensitivity to neutralization is determined by target and virus producer cell properties. AIDS 23: 1659-1667.
67. Heyndrickx, L., A. Heath, E. Sheik-Khalil, J. Alcami, V. Bongertz, M. Jansson, M. Malnati, D. Montefiori, C. Moog, L. Morris, et al. 2012. International network for comparison of HIV neutralization assays: the NeutNet report II. PLoS One 7: e36438.
68. Paul, S., S. Planque, Y. Nishiyama, M. Escobar, and C. Hanson. 2010. Back to the future: covalent epitope-based HIV vaccine development. Expert Rev. Vaccines 9: 1027-1043.
69. Kabat, E. A., T. T. Wu, H. M. Perry, K. S. Gottesman, and C. Foeller. 1991. Sequences of Proteins of Immunological Interest, 5th Ed. National Institutes of Health, Bethesda, MD, p. 91-3242.
70. Brochet, X., M. P. Lefranc, and V. Giudicelli. 2008. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 36(Web Server issue): W503-508.
71. Chang, B., and P. Casali. 1994. The CDR1 sequences of a major proportion of human germline Ig VH genes are inherently susceptible to amino acid replacement. Immunol. Today 15: 367-373.